William Blair analyst Raju Prasad maintained a Buy rating on PTC Therapeutics (PTCT) today. The company’s shares opened today at $45.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 18.1% and a 53.5% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Allogene Therapeutics Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on PTC Therapeutics is a Strong Buy with an average price target of $51.80.
See today’s analyst top recommended stocks >>
Based on PTC Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $72.11 million. In comparison, last year the company had a GAAP net loss of $9.52 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.
